di-n-butyl 2-naphthyl phosphate | 61555-56-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: di-n-butyl 2-naphthyl phosphate
• 英文别名: dibutyl 2-naphthyl phosphate；Dibutyl naphthalen-2-yl phosphate
• CAS: 61555-56-4
• 化学式: C₁₈H₂₅O₄P
• 分子量: 336.368
• InChiKey: MTQZVOBXNGHZKX-UHFFFAOYSA-N

物化性质

• 沸点：
  417.8±18.0 °C(Predicted)
• 密度：
  1.121±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  23
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  亚磷酸二丁酯 、 2-萘酚 在 potassium phosphate 、 联苯二碲 作用下， 以 乙腈 为溶剂， 以77 %的产率得到di-n-butyl 2-naphthyl phosphate
  参考文献：
  名称：

  以二苯二碲为有机催化剂合成磷酸酯

  摘要：

  这项工作展示了一种通过功能化萘酚和H-膦酸酯之间的脱氢磷酸化反应制备磷酸酯的方法，使用二苯基二碲化物作为有机催化剂和声化学作为替代能源。该方法也适用于α-萘酚、β-萘酚、苯酚和苯硫酚。

  DOI：

  10.1002/ejoc.202300021

文献信息

• Butyrylcholinesterase Inhibitors
  申请人：JAL Therapeutics, LLC

  公开号：US20160206635A1

  公开（公告）日：2016-07-21

  Butyrylcholinesterase inhibitors, their formulation, and their use primarily in the treatment of neurodegenerative diseases. These inhibitors generally are phosphates, phosphonates, phosphinates, and phosphoramidates. These inhibitors can be incorporated in pharmaceutical compositions and administered to a patient in therapeutically effective amounts to treat neurodegenerative diseases.

  丁酰胆碱酯酶抑制剂，它们的配方，以及它们主要用于治疗神经退行性疾病。这些抑制剂通常是磷酸酯、膦酸酯、膦酸酯和磷酰胺酯。这些抑制剂可以被纳入药物组成，并以治疗有效量的方式给患者使用，以治疗神经退行性疾病。
• BUTYRYLCHOLINESTERASE INHIBITORS
  申请人：Acey Roger A.

  公开号：US20100069337A1

  公开（公告）日：2010-03-18

  Butyrylcholinesterase inhibitors, their formulation, and their use primarily in the treatment of neurodegenerative diseases. These inhibitors generally are phosphates, phosphonates, phosphinates, and phosphoramidates. These inhibitors can be incorporated in pharmaceutical compositions and administered to a patient in therapeutically effective amounts to treat neurodegenerative diseases.

  丁酰胆碱酯酶抑制剂，它们的配方，主要用于治疗神经退行性疾病。这些抑制剂通常是磷酸酯、膦酸酯、膦酸酯和磷酰胺酯。这些抑制剂可以被纳入药物组合物中，并以治疗有效剂量的形式给患者使用，以治疗神经退行性疾病。
• Batra; Purnanand, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1991, vol. 30, # 1, p. 57 - 58
  作者：Batra、Purnanand

  DOI：——

  日期：——
• Synthesis, biochemical evaluation, and molecular modeling studies of aryl and arylalkyl di- n -butyl phosphates, effective butyrylcholinesterase inhibitors
  作者：Kensaku Nakayama、Jason P. Schwans、Eric J. Sorin、Trina Tran、Jeannette Gonzalez、Elvis Arteaga、Sean McCoy、Walter Alvarado

  DOI：10.1016/j.bmc.2017.04.002

  日期：2017.6

  A series of dialkyl aryl phosphates and dialkyl arylalkyl phosphates were synthesized. Their inhibitory activities were evaluated against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). The di-n-butyl phosphate series consistently displayed selective inhibition of BChE over AChE. The most potent inhibitors of butyrylcholinesterase were di-n-butyl-3,5-dimethylphenyl phosphate (4b) [ICy = 1.0 0.4 LM] and di-n-butyl 2-naphthyl phosphate (5b) [K-t=1.9 0.4 I.L.M]. Molecular modeling was used to uncover three subsites within the active site gorge that accommodate the three substituents attached to the phosphate group. Phosphates 4b and 5b were found to bind to these three subsites in analogous fashion with the aromatic groups in both analogs being accommodated by the "lower region," while the lone pairs on the P=0 oxygen atoms were oriented towards the oxyanion hole. In contrast, din-butyl-3,4-dimethylphenyl phosphate (4a) [K = 9 111M], an isomer of 4b, was found to orient its aromatic group in the "upper left region" subsite as placement of this group in the "lower region" resulted in significant steric hindrance by a ridge-like region in this subsite. Future studies will be designed to exploit these features in an effort to develop inhibitors of higher inhibitory strength against butyrylcholinesterase. (C) 2017 Elsevier Ltd. All rights reserved.
• BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Mgp Biotechnologies, Inc.

  公开号：EP2097428A2

  公开（公告）日：2009-09-09